


# Measles and rubella elimination country profile

## Andorra

### Measles elimination status

2016 eliminated  
2017 eliminated



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: [www.euro.who.int/7thrv](http://www.euro.who.int/7thrv)

### Rubella elimination status


2016 eliminated  
2017 eliminated



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: [www.euro.who.int/7thrv](http://www.euro.who.int/7thrv)

### Measles and rubella surveillance

National case-based surveillance for measles, rubella and CRS  
Lab confirmation for diagnosis of measles rubella and CRS



Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

### Demographic information, 2017

Total population	76 965
< 1 year old	676
< 5 years old	3341

Source: World Population Prospects: The 2017 Revision, New York, United Nations


### Measles and rubella immunization schedule, 2017

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	12 months	MCV2	1991
MCV2	MMR	3 years	RCV	1988
Measles vaccination in school				No

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance ([http://www.who.int/immunization/monitoring\\_surveillance/data/en/](http://www.who.int/immunization/monitoring_surveillance/data/en/))

MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

### Measles and rubella cases and immunization coverage, 2008–2017




Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance

([http://www.who.int/immunization/monitoring\\_surveillance/data/en/](http://www.who.int/immunization/monitoring_surveillance/data/en/))

MCV1 = first dose of measles-containing vaccine  
MCV2 = second dose of measles-containing vaccine

### Definition used for an outbreak

Two or more measles or rubella cases which are temporally related and epidemiologically linked, or both



Source: Measles and rubella elimination Annual Status Update report, 2017

### Information on CRS, 2017

No cases reported



Source: Measles and rubella elimination Annual Status Update report, 2017  
CRS = congenital rubella syndrome



# Measles and rubella elimination country profile

## Andorra

### Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected measles cases	Confirmed measles cases				Discarded as non-measles	Measles incidence	Genotypes detected
		Laboratory	Epi-linked	Clinically	Total			
2013	1	0	0	0	0	1	0	NA
2014	1	0	0	0	0	1	0	NA
2015	0	0	0	0	0	0	0	NA
2016	0	0	0	0	0	0	0	NA
2017	0	0	0	0	0	0	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017  
Incidence calculated per 1 million population  
ND = Data not available; NA= Not applicable

### Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non-measles rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	NA	ND	NA	NA	1	0	NA	NA
2014	NA	ND	NA	NA	1	0	NA	NA
2015	NA	NA	NA	NA	0	0	NA	NA
2016	NA	NA	NA	NA	0	0	NA	NA
2017	0	0%	NA	NA	0	0%	NA	NA

Source: ASU 2013-2017  
ND = Data not available; NA= Not applicable  
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

### Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected rubella cases	Confirmed rubella cases				Discarded as non-rubella	Rubella incidence	Genotypes detected
		Laboratory	Epi-linked	Clinically	Total			
2013	0	0	0	0	0	0	0	NA
2014	0	0	0	0	0	0	0	NA
2015	0	0	0	0	0	0	0	NA
2016	0	0	0	0	0	0	0	NA
2017	0	0	0	0	0	0	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017  
Incidence calculated per 1 million population  
ND = Data not available; NA= Not applicable

### Rubella surveillance and laboratory performance indicators, 2013-2017

	Discarded non-rubella rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	NA	NA	NA	NA	NA	NA	NA	NA
2014	NA	NA	NA	NA	NA	NA	NA	NA
2015	NA	NA	NA	NA	NA	NA	NA	NA
2016	NA	NA	NA	NA	NA	NA	NA	NA
2017	0	0%	NA	NA	0	0%	NA	NA

Source: ASU 2013-2017  
ND = Data not available; NA= Not applicable  
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

### RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Andorra in 2017 and confirmed that measles and rubella elimination has been sustained. RVC notes the continued increase in MRCV2 coverage and would appreciate additional activities keeping that trend.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: [www.euro.who.int/7thrv](http://www.euro.who.int/7thrv)

### Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: ≥ 80%
- % origin of infection known: ≥ 80%
- Rate of viral detection: ≥ 80%